Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI363 + Bevacizumab +/- Nab-Paclitaxel in Advanced Gastric Cancer
NCT07361991Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2026
- Primary completion
- Sep 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of IBI363 in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Incidence and Severity of Adverse Events and Overall Survival at 12 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
IBI363
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07361991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361991.